Collaborations

Partnering with Leaders in Cancer Immunotherapy

As with many transformative efforts, changing the paradigm of cancer treatment requires partnerships with other leaders in the field to develop next-generation technologies and products. Guided by this principle, we are collaborating with world-renowned academic institutions and industry leaders.

Are you interested in partnering with Kite?

We are actively exploring new partnership opportunities focused on enabling technologies and capabilities designed to bring life-saving therapies to patients. Please contact us at business@kitepharma.com.

Joint Ventures

FosunKite

Kite and Fosun Pharma formed FosunKite, a joint venture to develop, manufacture and commercialize axicabtagene ciloleucel in China with the option to include additional products, including two TCR product candidates from Kite.

Fosun Pharma

Strategic Collaborations

The National Cancer Institute (NCI)

Kite and NCI are in a Cooperative Research and Development Agreement to develop multiple engineered autologous cell therapy product candidates for the treatment of advanced hematological and solid malignancies..

Dr. Steve Rosenberg, Chief of Surgery at the National Cancer Institute, was interviewed by BioCentury TV to discuss his viewpoint and perspectives on recent advances in cancer immunotherapy.

National Cancer Institute

Daiichi Sankyo

Kite and Daiichi Sankyo established a strategic relationship to develop and commercialize axicabtagene ciloleucel in Japan with the option to license additional Kite product candidates for Japan including KITE-718, Kite’s TCR product candidate targeting MAGE-A3/A6 and certain other product candidates.

Daiichi Sankyo

The Leukemia & Lymphoma Society (LLS)

LLS has joined with Kite in a collaboration to enhance the development of KTE-C19 in refractory aggressive non-Hodgkin lymphoma and launch CAR T cell therapy educational programs.

The Leukemia & Lymphoma Society

CAR

Amgen

Kite and Amgen are in a collaboration to research and develop novel chimeric antigen receptor (CAR) T cell therapies leveraging Amgen’s oncology targets.

Amgen

Genentech

Kite and Genentech have entered into a clinical trial collaboration to evaluate the safety and efficacy of KTE-C19, in combination with atezolizumab (Genentech’s investigational anti-PDL1 antibody), in patients with refractory, aggressive NHL.

Genentech

Cell Design Labs

Kite and Cell Design Labs entered into a research collaboration and license agreement to develop next generation, precision-controlled chimeric antigen receptor (CAR) product candidates that incorporate molecular “on/off switch” technology.

Cell Design Labs

Adimab

Kite and Adimab are in a collaboration for the discovery and optimization of fully human antibodies against CAR targets selected by Kite.

Adimab

Tel-Aviv Sourasky Medical Center

Kite and Tel-Aviv Sourasky Medical Center are in a collaboration to research and develop novel CAR T cell therapies for various tumor types.

Tel-Aviv Sourasky Medical Center

TCR

The Netherlands Cancer Institute (NKI)

Kite and NKI have entered into an agreement under which Kite will receive from the NKI the exclusive option to license multiple T cell receptor (TCR) gene sequences for the development and commercialization of cancer immunotherapy candidates targeting solid tumors.

Dr. Ton Schumacher, Chief Scientific Officer of Kite Pharma EU, is also a Principal Investigator at The Netherlands Cancer Institute, where he also serves as Deputy Director.

The Netherlands Cancer Institute

Leiden University Medical Center (LUMC)

Kite and LUMC have entered into a Research and License Agreement to identify and develop TCR product candidates targeting solid tumors that are associated with HPV type 16 infection.

Leiden University Medical Center (LUMC)

bluebird bio

Kite and bluebird bio are in a collaboration to advance second generation TCR product candidates directed against the HPV-16 E6 oncoprotein leveraging bluebird bio’s lentiviral gene delivery and gene-editing capabilities.

bluebird bio

Enabling Technologies

General Electric

Kite and GE Global Research are in a strategic research collaboration to develop a next generation functionally integrated and automated manufacturing system for engineered T cell therapy.

General Electric

Vineti

Kite and Vineti have entered into a strategic partnership to design and develop a software platform for patients, physicians and treatment centers that enables commercial-scale ordering, logistics, monitoring and delivery of autologous cell therapies.

Vineti

Alpine Immune Sciences (AIS)

Kite and AIS are in a research collaboration and exclusive license agreement to use AIS’ Transmembrane Immunomodulatory Protein Technology (TIP™) for Kite’s CAR and TCR programs to enhance the immune response in the tumor microenvironment.

Alpine Immune Sciences

The UCLA David Geffen School of Medicine

Several of Kite’s scientific leaders are affiliated with UCLA, and Kite also entered into a license agreement to acquire rights to develop and commercialize technology for the development of off-the-shelf allogeneic T-cell therapies from renewable pluripotent stem cells.

The UCLA David Geffen School of Medicine